Cocrystal Pharma Inc Dossier
Qualitative Analysis
Business overview
Cocrystal Pharma, Inc. (Nasdaq: COCP) is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of high-value viral pathogens. Utilizing a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise, the company designs small-molecule antivirals to be safe, broad-spectrum, resistant to mutations, and convenient to administer. Cocrystal's pipeline focuses on major unmet medical needs, including noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and hepatitis C viruses. Its business model centers on early-stage discovery and clinical development, aiming to secure research collaborations, licensing agreements, and milestone-based partnerships with larger pharmaceutical companies rather than establishing independent commercial manufacturing or sales operations.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing CDI-988, the first oral direct-acting antiviral candidate targeting the highly conserved 3CL protease, into a Phase 1b human challenge study for the prevention and treatment of norovirus.
Expected impact: Establish proof-of-concept in a market with no approved antiviral therapies or vaccines, addressing a $60 billion global economic burden.
Planning an additional Phase 2a human challenge study for oral CC-42344 (PB2 inhibitor) for seasonal and pandemic influenza A, following inconclusive efficacy analyses in the initial Phase 2a study due to low infectivity of the challenge strain.
Expected impact: Validate clinical endpoints and therapeutic efficacy against influenza A, including highly pathogenic avian strains like H5N1.
Leveraging the proprietary structure-based drug discovery platform to discover and design novel direct-acting antivirals targeting highly conserved regions of replication enzymes in hantavirus, bunyavirus, and influenza.
Expected impact: Broaden the early-stage pipeline with candidates that maintain potency against mutating viral strains.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
The collaboration focused on developing influenza A/B antiviral compounds. Merck terminated the agreement effective March 14, 2024, due to the inability to meet a specific aspect of Merck's program, returning sole responsibility for further development of the discovered compounds to Cocrystal.
Terms: Cocrystal received an upfront payment of $4.0 million in 2019 and was eligible for up to $156.0 million in milestone payments plus royalties prior to termination.